West Virginia University Logo

Disease Site: Melanoma and Other Skin Cancers

9 protocol(s) meet the specified criteria

  • 16-009496Oncologic Outcomes Following Minimally Invasive Inguinal Lymphadenectomy for Melanoma
  • CMP-001-001A Multicenter, Open-Label, Phase Ib Clinical Study of CMP-001 in Combination with Pembrolizumab in Subjects with Advanced Melanoma
  • CO39722A Phase III, Open-Label, Multicenter, Two-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib plus Atezolizumab vs Pembrolizumab in Patients with Previously Untreated Advanced BRAFv600 Wild-Type Melanoma
  • DV3-MEL-01A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
  • EA6134A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
  • EAY131Molecular Analysis for Therapy Choice (MATCH)
  • INCMGA-0012-201A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma
  • LOXO-TRK-15002A Phase II Basket Study of Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors
  • S1616A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent